Brain glutamate levels in patients who experienced a psychosis: The GLUP study

Brain glutamate levels in patients who experienced a psychosis: The GLUP study - GLUP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47254

Enrollment

100

Registered

2016-01-27

Start date

2017-09-11

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychosis

Interventions

None listed

Eligibility

Age

12 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:;Inclusion criteria for all subjects (patients and healthy controls): * 16-40 years old. * Written informed consent of the subject;Patients who experienced a psychosis: * Psychosis (ICD-10 criteria for any functional psychotic illness: F10-19, excluding coding F1x.0 for Acute intoxication; F20-29 and F30-39, psychotic codings).

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study:;General exclusion criteria for all individuals: - Use of certain drugs and medication - Any previous neurosurgery or neurological disorder, including epilepsy - Any contraindications for MRI - Subjects who do not fully comprehend the purpose or are not competent to make a rational decision whether or not to participate - Patients who were admitted to a psychiatric unit involuntarily after being given an *inbewaringstelling* (IBS). Patients with *rechterlijke machtigingen* (RM) may be included, but only if they are mentally competent (see section on mental competence and decisional capacity above). The reasons for including these patients are that this will increase the likelihood of attaining the projected number of study participants and that inclusion of these patients will contribute to assembling a study population representative of all Dutch patients. ;Additional exclusion criteria for healthy controls: - Current Axis-I psychiatric disorder

Design outcomes

Primary

Measure	Time frame
Primary study parameter: - High-resolution brain glutamate levels.	—

Secondary

Measure	Time frame
Secondary study parameters: - Symptom severity in patients who experienced a psychosis o Short cognitive test battery o Positive and negative symptoms (Positive and Negative Symptoms Scale (PANNS)) o Functional impairment (using the Manchester Short Assessment of Quality of Life) - Structural (brain volumes) and functional (resting state BOLD signal) brain parameters. - (epi)Genetic variation in glutamatergic genes.	—

Measure

Time frame

Secondary study parameters: - Symptom severity in patients who experienced a psychosis o Short cognitive test battery o Positive and negative symptoms (Positive and Negative Symptoms Scale (PANNS)) o Functional impairment (using the Manchester Short Assessment of Quality of Life) - Structural (brain volumes) and functional (resting state BOLD signal) brain parameters. - (epi)Genetic variation in glutamatergic genes.

—

Countries

Netherlands

Outcome results